Evidence map›Paper›PMID 24880141›Full record

ArticleGynecologic oncology2014

Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.

Monica N Schointuch, Timothy P Gilliam, Jessica E Stine, Xiaoyun Han, Chunxiao Zhou, Paola A Gehrig, Kenneth Kim, Victoria L Bae-Jump

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 3 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Statins as Repurposed Drugs in Gynecological Cancer: A Review.International journal of molecular sciences · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. The emerging role of cholesterol metabolism in gynecologic cancer development and therapy.Apoptosis : an international journal on programmed cell death · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Monica N SchointuchDivision of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA.
Timothy P GilliamDivision of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA.
Jessica E StineDivision of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA.
Xiaoyun HanShanDong Tumor Hospital, Jinan University, Division of Gynecologic Oncology, Jinan 250117, PR China.
Chunxiao ZhouDivision of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA.
Paola A GehrigDivision of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Kenneth KimDivision of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Victoria L Bae-JumpDivision of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: victoria_baejump@med.unc.edu.
University of North Carolina at Chapel Hill · USUNC Lineberger Comprehensive Cancer CenterShandong Tumor Hospital · CN

Funding

Metformin as a Novel Chemotheraeutic Strategy for the Treatment of Endometrial CaK23CA143154 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BAE-JUMP, VICTORIA LIN · 2010 to 2014
$854k
NCI NIH HHS 1K23CA143154-01A1NCI NIH HHS K23 CA143154NCI NIH HHS L30 CA136170
6 · The paper itself

Abstract

objectiveOur goal was to evaluate the effects of simvastatin on endometrial cancer cell lines and primary cultures of endometrial cancer cells.

methodsCell proliferation in the ECC-1 and Ishikawa endometrial cancer cell lines and primary cultures of endometrial cancer cells was assessed by MTT assay. Apoptosis and cell cycle were detected by Annexin V assay and propidium iodide staining, respectively. Reactive oxygen species and cell adhesion were assessed using ELISA assays. Invasion was analyzed using a transwell invasion assay. Mitochondrial DNA damage was confirmed using qPCR. The effects of simvastatin on the AKT/mTOR and MAPK pathways were determined by Western blotting.

resultsSimvastatin inhibited cell proliferation in a dose-dependent manner in both endometrial cancer cell lines and 5/8 primary cultures of endometrial cancer cells. Simvastatin treatment resulted in G1 cell cycle arrest, a reduction in the enzymatic activity of HMG-CoA, induction of apoptosis as well as DNA damage and cellular stress. Treatment with simvastatin resulted in inhibition of the MAPK pathway and exhibited differential effects on the AKT/mTOR pathway in the ECC-1 and Ishikawa cells. Minimal change in AKT phosphorylation was seen in both cell lines. An increase in phosphorylated S6 was seen in ECC-1 and a decrease was seen in Ishikawa. Treatment with simvastatin reduced cell adhesion and invasion (p<0.01) in both cell lines.

conclusionSimvastatin had significant anti-proliferative and anti-metastatic effects in endometrial cancer cells, possibly through modulation of the MAPK and AKT/mTOR pathways, suggesting that statins may be a promising treatment strategy for endometrial cancer.

Indexed as

ApoptosisCell AdhesionCell ProliferationEndometrial NeoplasmsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsNeoplasm InvasivenessNeoplasm MetastasisSimvastatinTumor Cells, CulturedHydroxymethylglutaryl-CoA Reductase InhibitorsSimvastatinAKT/mTOR pathwayEndometrial cancerInvasionMAPK pathwaySimvastatinStatins

Identifiers

PMID24880141
PMCPMC4125536
OpenAlexW1963541055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.